Kogenate® FS antihemophilic factor (recombinant)

Kovaltry® Antihemophilic Factor (Recombinant)

Jivi® antihemophilic factor (recombinant) PEGylated-aucl

BAYER

Post Hoc Subgroup Analysis:

Kogenate® FS* On-Demand Patients Transitioned to Jivi® or Kovaltry® as Part of Clinical Trials

*Also includes patients who transitioned from Helixate FS. Kogenate FS and Helixate FS contain the same factor (active pharmaceutical ingredient and formulation).

INDICATION FOR KOGENATE FS

KOGENATE FS is an Antihemophilic Factor (Recombinant) indicated for:

- On-demand treatment and control of bleeding episodes in adults and children with hemophilia A.
- Perioperative management of bleeding in adults and children with hemophilia A.
- Routine prophylaxis to reduce the frequency of bleeding episodes in children with hemophilia A and to reduce the risk of joint damage in children without pre-existing joint damage.
- Routine prophylaxis to reduce the frequency of bleeding episodes in adults with hemophilia A.

INDICATION FOR KOVALTRY

KOVALTRY Antihemophilic Factor (Recombinant) is a recombinant human DNA sequence derived, full length Factor VIII concentrate indicated for use in adults and children with hemophilia A for:

- On-demand treatment and control of bleeding episodes
- Perioperative management of bleeding
- Routine prophylaxis to reduce the frequency of bleeding episodes

SELECTED IMPORTANT SAFETY INFORMATION ABOUT KOGENATE FS, KOVALTRY AND JIVI

- KOGENATE FS, KOVALTRY, or JIVI are contraindicated in patients who have a history of hypersensitivity reactions to the active substance, to any of the excipients, or to mouse or hamster proteins. JIVI is also contraindicated in patients who have a history of hypersensitivity reactions to polyethylene glycol (PEG).

Please see additional Important Safety Information throughout and the full Prescribing Information for KOGENATE FS, KOVALTRY and JIVI.

The Bayer Hemophilia A Portfolio



1. Kogenate Prescribing Information. Bayer HealthCare LLC, Whippany, NJ. 2. Kovaltry Prescribing Information. Bayer HealthCare LLC, Whippany, NJ; 2016. 3. Jivi Prescribing Information. Bayer HealthCare LLC, Whippany, NJ; 2018.

INDICATION FOR JIVI

JIVI antihemophilic factor (recombinant), PEGylated-aucl, is a recombinant DNA-derived, Factor VIII concentrate indicated for use in previously treated adults and adolescents (12 years of age and older) with hemophilia A (congenital Factor VIII deficiency) for:

- On-demand treatment and control of bleeding episodes
- Perioperative management of bleeding
- Routine prophylaxis to reduce the frequency of bleeding episodes

LIMITATIONS OF USE FOR JIVI:

- JIVI is not indicated for use in children less than 12 years of age due to a greater risk for hypersensitivity reactions.
- JIVI is not indicated for use in previously untreated patients (PUPs).

KOGENATE FS, KOVALTRY, and JIVI are not indicated for the treatment of von Willebrand disease.

SELECTED IMPORTANT SAFETY INFORMATION ABOUT KOGENATE FS, KOVALTRY AND JIVI

- KOGENATE FS, KOVALTRY, or JIVI may contain trace amounts of mouse and hamster proteins. Patients treated with KOGENATE FS, KOVALTRY, or JIVI may develop hypersensitivity to these non-human mammalian proteins.

Please see additional Important Safety Information throughout and the full Prescribing Information for KOGENATE FS, KOVALTRY and JIVI.

Kogenate FS antihemophilic factor (recombinant)

Kovaltry Antihemophilic Factor (Recombinant)

Kovaltry®: Efficacy and safety for on-demand treatment in adolescents and adults, including those who transitioned from Kogenate® FS[2,4,5]

LEOPOLD II Clinical Trial (N=21)

The safety and efficacy of Kovaltry® for on-demand treatment in adolescent and adult (12 to 65 years of age) previously treated patients (PTPs) was evaluated for 12 months.[2,4]



21.6% of total bleeds were trauma bleeds.[4]

75.5%
1 infusion[4]

19.7%
2 infusions[4]

4.8%
3+ infusions[4]

0 Inhibitors
in the main study analysis of 21 previously treated patients.[4]

One patient in the on-demand group (n=21) experienced a mild drug-related adverse event (infusion site pruritus).[4]

10 Kogenate FS on-demand patients transitioned to Kovaltry on-demand as part of the clinical trial.[4]

Subgroup analysis (N=10)

15.9% of total bleeds were trauma bleeds.[4]

85.9%
1 infusion[4]

10.8%
2 infusions[4]

3.3%
3+ infusions[4]

0 Inhibitors
in the subgroup analysis of 10 previously treated patients.[4]

There were no drug-related adverse events in the subgroup.[5]

The on-demand arm in the LEOPOLD II clinical trial and the subgroup analysis both included patients with Hepatitis B, Hepatitis C, and HIV.[4]

2. Kovaltry Prescribing Information. Bayer HealthCare LLC, Whippany, NJ; 2021. 4. Data on file. Leopold II (14319) prior OD Kogenate FS/Helixate FS Cohort - Descriptive analysis. Bayer Healthcare LLC, Whippany, NJ. 5. Data on file. Leopold II (14319) prior OD Kogenate FS/Helixate FS Cohort. Bayer Healthcare LLC, Whippany, NJ.

SELECTED IMPORTANT SAFETY INFORMATION ABOUT KOGENATE FS, KOVALTRY AND JIVI®

- Hypersensitivity reactions, including severe allergic reactions, are possible with KOGENATE FS, KOVALTRY, or JIVI. Monitor patients for hypersensitivity symptoms. Early signs of hypersensitivity reactions, which can progress to anaphylaxis, may include chest or throat tightness, dizziness, mild hypotension and nausea. Discontinue KOGENATE FS, KOVALTRY, or JIVI if symptoms occur and seek immediate emergency treatment.
- Catheter-related infections may occur when KOVALTRY is administered via central venous access devices (CVADs). These infections have not been associated with the product itself.
- KOGENATE FS, KOVALTRY, and JIVI may contain trace amounts of mouse and hamster proteins. Patients treated with KOGENATE FS, KOVALTRY, or JIVI may develop hypersensitivity to these non-human mammalian proteins.

Please see additional Important Safety Information throughout and the full Prescribing Information for KOGENATE FS, KOVALTRY and JIVI ANTIHEMOPHILIC FACTOR (RECOMBINANT) PEGYLATED-AUCL.

Kogenate FS antihemophilic factor (recombinant)

Jivi antihemophilic factor (recombinant) PEGylated-aucl

BAYER

Jivi®: Efficacy and safety for on-demand treatment in adolescents and adults, including those who transitioned from Kogenate® FS[3,6,7]

PROTECT VIII Clinical Trial (N=20)

The safety and efficacy of Jivi® for on-demand treatment in adolescent and adult (12 to 65 years of age) previously treated patients (PTPs) was evaluated for 36 weeks.[3,6]



40.4% of total bleeds were trauma bleeds.[6]

79.5%
1 infusion[6]

11.7%
2 infusions[6]

8.8%
3+ infusions[6]

0 Inhibitors
in the main study analysis of 20 previously treated patients.[6]

One patient in the on-demand group (n=20) experienced mild drug-related adverse events (dry mouth, musculoskeletal discomfort).[6]

10 Kogenate FS on-demand patients transitioned to Jivi on-demand as part of the clinical trial.[6]

Subgroup analysis (N=10)



36.0% of total bleeds were trauma bleeds.[6]

73.9%
1 infusion[6]

16.7%
2 infusions[6]

9.4%
3+ infusions[6]

0 Inhibitors
in the subgroup analysis of 10 previously treated patients.[6]

One patient in the on-demand subgroup group (n=10) experienced mild drug-related adverse events (dry mouth, musculoskeletal discomfort).[7]

The on-demand arm in the Protect VIII clinical trial and the subgroup analysis both included patients with Hepatitis B, Hepatitis C, and HIV.[6]

3. Jivi [antihemophilic factor (recombinant), PEGylated-aucl] Prescribing Information. 6. Data on file. Protect VIII (13024) prior OD Kogenate FS/Helixate FS Cohort Descriptive Analysis. Bayer Healthcare LLC, Whippany, NJ. 7. Data on file. Jivi Protect FVIII (13024) Subgroup- prior Kogenate FS/Helixate FS Cohort. Bayer Healthcare LLC, Whippany, NJ.

SELECTED IMPORTANT SAFETY INFORMATION ABOUT KOGENATE FS AND JIVI

In clinical trials with:

- KOGENATE FS – the most common adverse reactions (≥4%) observed were inhibitor formation in previously untreated and minimally treated patients, skin-related hypersensitivity reactions, infusion site reactions, and CVAD-associated infections.
- KOVALTRY – the most frequently reported adverse reactions in clinical trials (≥5%) were inhibitors in previously untreated patients (PUPs)/ minimally treated patients (MTPs), and pyrexia, headache, and rash.
- JIVI – the most frequently (≥5%) reported adverse reactions in previously treated patients (PTPs) ≥12 years of age were headache, cough, nausea, and fever.

Please see additional Important Safety Information throughout and the full Prescribing Information for KOGENATE FS, KOVALTRY® ANTIHEMOPHILIC FACTOR (RECOMBINANT) and JIVI.

Access Services by Bayer™

Kogenate® FS antihemophilic factor (recombinant)

Kovaltry® Antihemophilic Factor (Recombinant)

Jivi® antihemophilic factor (recombinant) PEGylated-aucl

BAYER

Reimbursement support, coverage, financial and affordability solutions

Patient Loyalty Program[15]

Bayer is committed to helping your patients start and stay on therapy regardless of changes in their commercial health insurance coverage status.

Eligible patients can receive Kogenate® FS, Kovaltry® or Jivi® at no cost if they experience gaps or changes with insurance coverage.

Enroll your patients now so they have access to the Patient Loyalty Program and all associated benefits!

Free Trial Program‡§

- Patients new to Kovaltry or Jivi can receive **1-month of free therapy.**
- Selected product is delivered to your patient's home.
- Any patient new to Kovaltry or Jivi is able to participate, regardless of type of insurance or if they have insurance.

$0 Co-Pay Program*†

- Eligible commercially insured patients can pay as low as $0 per prescription, regardless of income. **(Up to $12,000 in co-pay assistance** per year.)
- **Assistance is awarded per patient.** Multiple members of the same household can apply.
- Patients can enroll at **copaysupport.bayer.com** or in **one short phone call** to 1-647-245-5619.

Jivi Reimbursement for Lab Testing*†

- Eligible patients can receive up to $250 per year to offset out-of-pocket costs for laboratory testing of Jivi due to Jivi-specific assay requirements.

Live helpline support

CALL 1-800-288-8374 NOW!
Speak with a **health insurance expert**
9:00 AM–6:00 PM (ET) Monday–Friday
Multiple languages are available, including Spanish

Jivi and Kovaltry are covered for 99% of patients nationally¶#

*Co-pay program support is available for up to 1 year. Can include any out-of-pocket prescription costs, such as co-pay and co-insurance.
†Patients who are enrolled in any type of government insurance are not eligible. Bayer reserves the right to rescind, revoke, or amend this offer without notice at any time.
‡Participation in the Jivi or Kovaltry Free Trial Program is limited to 1 time only per product (patients currently using Jivi or Kovaltry are not eligible for a Free Trial of their current product). The Free Trial Program includes 1 month supply up to a maximum of 40,000 IU. The Free Trial Program for Jivi is available to patients 12 years of age and older. Bayer reserves the right to rescind, revoke, or amend this offer without notice at any time.
§The medication provided through this program is at no cost to the patient and is not contingent on future use of this medication. Reselling or billing any third party for free product provided by this program is prohibited by law.
¶Formulary status is believed to be accurate as of March 1, 2021 but cannot be guaranteed. Formulary status for national plans may not reflect plan variation at the local level. Lower co-pay costs do not necessarily reflect a cost advantage in the outcome of the condition treated because there are other variables that affect relative cost. Formulary status does not imply a comparison of efficacy, safety, or dosing.
#Jivi coverage includes pharmacy and medical lives across commercial (99%), fee-for-service Medicaid (100%), and Managed Medicaid (100%); it does not include Medicare (48%). Kovaltry coverage includes pharmacy and medical lives across commercial (99%), fee-for-service Medicaid (100%), and Managed Medicaid (100%); it does not include Medicare (49%). Percentage represents the coverage within the book of business. n=1,635, 51, 366.

SELECTED IMPORTANT SAFETY INFORMATION ABOUT KOGENATE FS AND JIVI

- For JIVI, a low post-infusion Factor VIII level in the absence of detectable Factor VIII inhibitors indicates that loss of drug effect is likely due to anti-PEG antibodies. Discontinue JIVI and switch patients to a previously effective Factor VIII product.

Please see additional Important Safety Information throughout and the full Prescribing Information for KOGENATE FS, KOVALTRY and JIVI.

Kogenate FS antihemophilic factor (recombinant)

Kovaltry Antihemophilic Factor (Recombinant)

Jivi antihemophilic factor (recombinant) PEGylated-aucl

BAYER

INDICATIONS FOR KOGENATE FS, KOVALTRY AND JIVI

INDICATION FOR KOGENATE® FS

KOGENATE FS is an Antihemophilic Factor (Recombinant) indicated for:
On-demand treatment and control of bleeding episodes in adults and children with hemophilia A.

- Perioperative management of bleeding in adults and children with hemophilia A.
- Routine prophylaxis to reduce the frequency of bleeding episodes in children with hemophilia A and to reduce the risk of joint damage in children without pre-existing joint damage.
- Routine prophylaxis to reduce the frequency of bleeding episodes in adults with hemophilia A.

INDICATION FOR KOVALTRY®

KOVALTRY Antihemophilic Factor (Recombinant) is a recombinant human DNA sequence derived, full length Factor VIII concentrate indicated for use in adults and children with hemophilia A for:

- On-demand treatment and control of bleeding episodes
- Perioperative management of bleeding
- Routine prophylaxis to reduce the frequency of bleeding episodes

INDICATION FOR JIVI®

JIVI antihemophilic factor (recombinant), PEGylated-aucl, is a recombinant DNA-derived, Factor VIII concentrate indicated for use in previously treated adults and adolescents (12 years of age and older) with hemophilia A (congenital Factor VIII deficiency) for:

- On-demand treatment and control of bleeding episodes
- Perioperative management of bleeding
- Routine prophylaxis to reduce the frequency of bleeding episodes

LIMITATIONS OF USE FOR JIVI:

- JIVI is not indicated for use in children less than 12 years of age due to a greater risk for hypersensitivity reactions.
- JIVI is not indicated for use in previously untreated patients (PUPs).

KOGENATE FS, KOVALTRY, and JIVI are not indicated for the treatment of von Willebrand disease.

IMPORTANT SAFETY INFORMATION ABOUT KOGENATE FS, KOVALTRY, AND JIVI

KOGENATE FS, KOVALTRY, and JIVI are contraindicated in patients who have a history of hypersensitivity reactions to the active substance, to any of the excipients, or to mouse or hamster proteins. JIVI is also contraindicated in patients who have a history of hypersensitivity reactions to polyethylene glycol (PEG).

Hypersensitivity reactions, including severe allergic reactions, are possible with KOGENATE FS, KOVALTRY, and JIVI. Monitor patients for hypersensitivity symptoms. Early signs of hypersensitivity reactions, which can progress to anaphylaxis, may include chest or throat tightness, dizziness, mild hypotension and nausea. Discontinue KOGENATE FS, KOVALTRY, or JIVI if symptoms occur and seek immediate emergency treatment.

KOGENATE FS, KOVALTRY, and JIVI may contain trace amounts of mouse and hamster proteins. Patients treated with KOGENATE FS, KOVALTRY, or JIVI may develop hypersensitivity to these non-human mammalian proteins.

Please see additional Important Safety Information throughout and the full Prescribing Information for KOGENATE FS, KOVALTRY and JIVI.

Kogenate FS antihemophilic factor (recombinant)

Kovaltry Antihemophilic Factor (Recombinant)

Jivi antihemophilic factor (recombinant) PEGylated-aucl

BAYER

IMPORTANT SAFETY INFORMATION (CONTINUED)

Neutralizing antibodies (inhibitors) have occurred following administration of KOGENATE FS, KOVALTRY, and JIVI predominately in previously untreated patients. Carefully monitor patients for the development of Factor VIII inhibitors, using appropriate clinical observations and laboratory tests. If expected plasma Factor VIII activity levels are not attained, or if bleeding is not controlled with an expected dose, suspect the presence of an inhibitor.

For JIVI, a clinical immune response associated with IgM anti-PEG antibodies, manifested as symptoms of acute hypersensitivity and/or loss of drug effect, has been observed primarily in patients < 6 years of age. The symptoms of the clinical immune response were transient. Anti-PEG IgM titers decreased over time to undetectable levels. No immunoglobulin class switching was observed. In case of clinical suspicion of loss of drug effect, conduct testing for Factor VIII inhibitors and Factor VIII recovery.

For JIVI, a low post-infusion Factor VIII level in the absence of detectable Factor VIII inhibitors indicates that loss of drug effect is likely due to anti-PEG antibodies. Discontinue JIVI and switch patients to a previously effective Factor VIII product.

Hemophilic patients with cardiovascular risk factors or diseases may be at the same risk to develop cardiovascular events as non-hemophilic patients when clotting has been normalized by treatment with Factor VIII.

Catheter-related infections may occur when KOVALTRY is administered via central venous access devices (CVADs). These infections have not been associated with the product itself.

In clinical trials with:

- KOGENATE FS – the most common adverse reactions (≥4%) observed were inhibitor formation in previously untreated and minimally treated patients, skin-related hypersensitivity reactions, infusion site reactions, and CVAD-associated infections.
- KOVALTRY – the most frequently reported adverse reactions in clinical trials (≥5%) were inhibitors in previously untreated patients (PUPs)/ minimally treated patients (MTPs), and pyrexia, headache, and rash.
- JIVI – the most frequently (≥5%) reported adverse reactions in previously treated patients (PTPs) ≥12 years of age were headache, cough, nausea, and fever.

For additional important risk and use information, please see the full Prescribing Information for KOGENATE FS, KOVALTRY, and JIVI.

You are encouraged to report side effects or quality complaints of prescription drugs to the FDA. Visit **www.fda.gov/medwatch** or call 1-800-FDA-1088.

Please see additional Important Safety Information throughout and the full Prescribing Information for KOGENATE FS, KOVALTRY and JIVI.